Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Welcome,         Profile    Billing    Logout  
 11 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maio, Michele
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Active, not recruiting
3
214
Europe
L19IL2 + L19TNF, Surgery
Philogen S.p.A.
Malignant Melanoma
10/24
12/28
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy

Active, not recruiting
2/3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
10/24
10/25
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
185
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
07/25
07/25
NCT02076646: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Active, not recruiting
1/2
96
Europe
L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC, DETICENE®
Philogen S.p.A.
Metastatic Melanoma Stage IV
05/16
06/22
NCT05586516: A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Recruiting
1/2
24
Europe
IOA-289, gemcitabine, nab-paclitaxel, Abraxane
iOnctura
Metastatic Pancreatic Cancer
12/24
02/25
OMNIA-1, NCT05578872: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Recruiting
1/2
130
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
09/24
12/24
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
KROCUS, NCT05756153: A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Zhejiang Genfleet Therapeutics Co., Ltd.
Advance Non-small Cell Lung Cancer
03/25
08/25
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23
DIONE-01, NCT04328844: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruiting
1
210
Europe
IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib
iOnctura
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
03/25
03/25
NCT04282083: Protocol ITANET - Registry

Recruiting
N/A
3600
Europe
Italian Association Neuroendocrine Tumors
Gastro-entero Pancreatic Neuroendocrine Tumors
07/27
07/32
Giacomo, Anna Maria Di
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Melanoma or Non-small Cell Lung Cancer

Recruiting
3
190
Europe
Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment
ETOP IBCSG Partners Foundation, USZ Foundation
Non-Small Cell Lung Cancer, Melanoma
01/26
12/26
NIBIT-ML1, NCT04250246: A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Not yet recruiting
2
184
Europe
Ipilimumab plus nivolumab plus guadecitabine, ipilimumab (Yervoy), nivolumab (Opdivo), guadecitabine (SGI-110), Ipilimumab plus nivolumab
Italian Network for Tumor Biotherapy Foundation, Astex Pharmaceuticals, Inc., Bristol-Myers Squibb
Melanoma, Non Small Cell Lung Cancer
03/23
03/25
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
PANDORA, NCT06086288: Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Not yet recruiting
2
35
Europe
Pembrolizumab, Etoposide, Cisplatin or Carboplatin
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Merkel Cell Carcinoma
12/27
12/27
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25

Download Options